News
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...
7d
Dealbreaker on MSNSanofi Extends Respiratory Vaccines Reach With $1.15B Acquisition of Clinical-Stage VicebioThe deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.
The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...
11h
New Scientist on MSNHuman trials point the way towards an mRNA vaccine against HIVWe may be a step closer to a highly effective mRNA vaccine against HIV, but tests so far reveal that the approach can cause ...
French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...
Sanofi SA (NASDAQ:SNY) on Tuesday agreed to acquire Vicebio Ltd, a privately held biotechnology company headquartered in ...
PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...
Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...
5d
News-Medical.Net on MSNNew model predicts mRNA protein production, accelerating drug and vaccine discoveryA new artificial intelligence model can improve the process of drug and vaccine discovery by predicting how efficiently ...
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held ...
French pharma giant Sanofi announced on Tuesday that it is to purchase London-based respiratory virus vaccine developer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results